Global viscosuppplementation revenues are likely to reach USD 4 billion by the end of 2030, according to a new research by ESOMAR-certified firm Future Market Insights.
According to the study, a number of broader, and industry-specific factors will drive growth in this market, which has been relatively less impacted by the sluggishness induced by COVID-19.
As per the UN, by 2050, those aged 60 and above will account for over 20% of the global population. In other words, the UN says that by 2050 around 130 Mn people will contract osteoarthritis. These numbers point towards growth in the viscosupplementation market in the forecast period.
Covid-19 Pandemic: Viscosuppplementation Market Players Consolidating their PositionThe ongoing Covid-19 pandemic has compelled the market players to take a consistent path for the next two quarters. As it would take some time for the healthcare vertical to look through new product launches; the players are looking at ways to smoothen the supply chain as manpower has taken a hit.
Continuous innovations are expected to propel the growth of viscosupplementation market” says the FMI analyst
To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-9509
Key Takeaways of Viscosupplementation Market Study
- Three injection viscosuppplementation is expected to contribute for more than 55% of revenue share
- Knee osteoarthritis is expected to gain around one-third of market share during the forecast period
- North America is the highest revenue generating market due to scientific advancements and high adoption of viscosuppplementation
New Product Development to be the TorchbearerThe market players are into the innovation mode to strengthen their foothold in the viscosupplementation market. This competitive landscape is all set to create ripples all across the market. Some of the innovations are:
- Fidia Pharma USA Inc., in 2019, introduced a HA (Hyaluronic Acid) based intra-articular viscosupplement called “TRILURON” to treat knee osteoarthritis. The treatments cycle involves 3 injections at weekly intervals.
- Japan-based Seikagaku Corporation, in Mar 2019, launched an intra-articular single-injection viscosupplement called “HyLink” in Italy for treating knee osteoarthritis.
- Recently, Gel-One Hyaluronate was approved as one of the injectable gels to treat osteoarthritis of knee. The pre-market clinical study reported no pseudosepsis (severe acute inflammatory responses).
Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-9509
Want more insights?Viscosupplementation market, a new study from Future Market Insights, opines on the viscosupplementation from 2015 – 2019 and presents demand projections from 2020 – 2030 on the basis of; product types (single injection viscosupplementation, three injection viscosupplementation, and five injection viscosupplementation), application (knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, and others such as elbow and ankle joint osteoarthritis), and end user (hospitals, ambulatory surgical centers, orthopedic clinics, retail pharmacies, and online sales) across seven prominent regions.
Viscosupplementation Market: SegmentationThe global viscosupplementation market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Product Type
- Single Injection Viscosupplementation
- Three Injection Viscosupplementation
- Five Injection Viscosupplementation
Application
- Knee Oseteoarthritis
- Hip Oseteoarthritis
- Shoulder Oseteoarthritis
- Others
End User
- Hospitals
- Ambulatory Surgical Centers
- Orthopedic Clinics
- Retail Pharmacies
- Online Sales
For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/9509
Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa (MEA)